327 related articles for article (PubMed ID: 32293299)
1. Baseline levels of dynamic CD4
Allner C; Melde M; Becker E; Fuchs F; Mühl L; Klenske E; Müller L; Morgenstern N; Fietkau K; Hirschmann S; Atreya R; Atreya I; Neurath MF; Zundler S
BMC Gastroenterol; 2020 Apr; 20(1):103. PubMed ID: 32293299
[TBL] [Abstract][Full Text] [Related]
2. Mucosal α4β7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis.
Roosenboom B; Wahab PJ; Smids C; Meijer J; Kemperman LGJM; Groenen MJM; van Lochem EG; Horjus Talabur Horje CS
Inflamm Bowel Dis; 2024 Jun; 30(6):930-938. PubMed ID: 37436917
[TBL] [Abstract][Full Text] [Related]
3. The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo.
Zundler S; Fischer A; Schillinger D; Binder MT; Atreya R; Rath T; Lopez-Pósadas R; Voskens CJ; Watson A; Atreya I; Neufert C; Neurath MF
Inflamm Bowel Dis; 2017 Mar; 23(3):379-391. PubMed ID: 28221249
[TBL] [Abstract][Full Text] [Related]
4. Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s.
Binder MT; Becker E; Wiendl M; Schleier L; Fuchs F; Leppkes M; Atreya R; Neufert C; Atreya I; Neurath MF; Zundler S
Inflamm Bowel Dis; 2018 May; 24(6):1237-1250. PubMed ID: 29788362
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
Domènech E; Gisbert JP
Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
[TBL] [Abstract][Full Text] [Related]
6. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
Boden EK; Shows DM; Chiorean MV; Lord JD
Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
[TBL] [Abstract][Full Text] [Related]
7. Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab.
Domenis R; Marino M; Cifù A; Scardino G; Curcio F; Fabris M
PLoS One; 2020; 15(11):e0242342. PubMed ID: 33180848
[TBL] [Abstract][Full Text] [Related]
8. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
Soler D; Chapman T; Yang LL; Wyant T; Egan R; Fedyk ER
J Pharmacol Exp Ther; 2009 Sep; 330(3):864-75. PubMed ID: 19509315
[TBL] [Abstract][Full Text] [Related]
9. Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations.
Van den Berghe N; Verstockt B; Gils A; Sabino J; Ferrante M; Vermeire S; Declerck P; Thomas D
J Crohns Colitis; 2021 Jun; 15(6):988-993. PubMed ID: 33245363
[TBL] [Abstract][Full Text] [Related]
10. Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.
Paul S; Williet N; Di Bernado T; Berger AE; Boschetti G; Filippi J; Del Tedesco E; Nancey S; Flourie B; Roblin X
J Crohns Colitis; 2018 Aug; 12(9):1089-1096. PubMed ID: 29860366
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab.
Wyant T; Estevam J; Yang L; Rosario M
Cytometry B Clin Cytom; 2016 Mar; 90(2):168-76. PubMed ID: 25908521
[TBL] [Abstract][Full Text] [Related]
12. Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases.
Kim EM; Randall C; Betancourt R; Keene S; Lilly A; Fowler M; Dellon ES; Herfarth HH
Inflamm Bowel Dis; 2020 Jul; 26(8):1232-1238. PubMed ID: 31633167
[TBL] [Abstract][Full Text] [Related]
13. Vedolizumab Efficacy Is Associated With Decreased Intracolonic Dendritic Cells, Not Memory T Cells.
Boden EK; Kongala R; Hindmarch DC; Shows DM; Juarez JG; Lord JD
Inflamm Bowel Dis; 2024 May; 30(5):704-717. PubMed ID: 37837660
[TBL] [Abstract][Full Text] [Related]
14. Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis.
Veny M; Garrido-Trigo A; Corraliza AM; Masamunt MC; Bassolas-Molina H; Esteller M; Arroyes M; Tristán E; Fernández-Clotet A; Ordás I; Ricart E; Esteve M; Panés J; Salas A
J Crohns Colitis; 2021 Mar; 15(3):441-452. PubMed ID: 32926095
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis.
Battat R; Dulai PS; Vande Casteele N; Evans E; Hester KD; Webster E; Jain A; Proudfoot JA; Mairalles A; Neill J; Singh S; Chang JT; Rivera-Nieves J; Sandborn WJ; Boland BS
Inflamm Bowel Dis; 2019 Jan; 25(2):410-420. PubMed ID: 30295781
[TBL] [Abstract][Full Text] [Related]
16. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
17. Blockade of αEβ7 integrin suppresses accumulation of CD8
Zundler S; Schillinger D; Fischer A; Atreya R; López-Posadas R; Watson A; Neufert C; Atreya I; Neurath MF
Gut; 2017 Nov; 66(11):1936-1948. PubMed ID: 27543429
[TBL] [Abstract][Full Text] [Related]
18. Vedolizumab Antagonizes MAdCAM-1-Dependent Human Placental Cytotrophoblast Adhesion and Invasion In Vitro.
Blaisdell A; Zhou Y; Kattah MG; Fisher SJ; Mahadevan U
Inflamm Bowel Dis; 2022 Aug; 28(8):1219-1228. PubMed ID: 35349682
[TBL] [Abstract][Full Text] [Related]
19. Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease.
Schulze LL; Becker E; Dedden M; Liu LJ; van Passen C; Mohamed-Abdou M; Müller TM; Wiendl M; Ullrich KAM; Atreya I; Leppkes M; Ekici AB; Kirchner P; Stürzl M; Sexton D; Palliser D; Atreya R; Siegmund B; ; Neurath MF; Zundler S
J Crohns Colitis; 2023 Nov; 17(11):1817-1832. PubMed ID: 37208197
[TBL] [Abstract][Full Text] [Related]
20. Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing.
Schleier L; Wiendl M; Heidbreder K; Binder MT; Atreya R; Rath T; Becker E; Schulz-Kuhnt A; Stahl A; Schulze LL; Ullrich K; Merz SF; Bornemann L; Gunzer M; Watson AJM; Neufert C; Atreya I; Neurath MF; Zundler S
Gut; 2020 Feb; 69(2):252-263. PubMed ID: 31092589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]